A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508278-26-01

Enrollment

Registered

2024-03-18

Start date

2024-04-05

Completion date

Unknown

Last updated

2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium

None listed

Source: EU CTIS · Data processed: Feb 4, 2026